Novavax Still Rallying After Grant
The Grant That Continues To Rally the Stock
Novavax (NVAX) stock continues its ascent following yesterday’s announcement that the firm was granted up to $384 million by the coalition for Epidemic Preparedness innovation.
We remind that the grant is to help the advancement in the clinical development of the firm’s SARS-CoV-2 (COVID-19) vaccine and of scaling-up manufacturing.
We have to note that promising news for Novavax does not mean bad news for Moderna (MRNA). Many successful vaccine developments are needed against the novel coronavirus (COVID-19) by as many companies as possible in order to stop the pandemic. It’s the only possible way to defeat this silent unseen enemy of humanity.